1. Design an appropriate patient-specific treatment, supportive care, and monitoring plan taking into consideration efficacy and safety outcomes from clinical trials and current treatment guidelines for patients with bladder, renal, or testicular cancer.
2. Determine short- and long-term treatment goals, including post-therapy and survivorship, with a patient with bladder, renal, or testicular cancer and his or her caregiver.
3. Devise and communicate appropriate plans for preventing, monitoring, and treating adverse reactions associated with the treatment with tyrosine kinase inhibitors and mTOR inhibitors.